Loading clinical trials...
Loading clinical trials...
A Single-arm, Open, Multicenter, Phase II Study to Investigator the Efficacy and Safety of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
HYML-122; cytarabine
Locations
1
China
the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
March 29, 2022
Primary Completion Date
December 30, 2025
Completion Date
June 30, 2026
Last Updated
April 10, 2025
NCT06660368
NCT02074839
NCT05241106
NCT05345938
Lead Sponsor
Tarapeutics Science Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions